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Abstract: Background: Mesenchymal stem cells (MSCs) can be efficiently recruited to wound, inflammatory and 
tumor sites to repair and regenerate tissue. However, its role in colitis and colitis associated colon cancer is still con-
troversial. This study was designed to evaluate the role and mechanisms of inflammatory cytokines-activated-MSCs 
in mice colitis and colon cancer. Methods: We selected two well-characterized pro-inflammatory cytokines, tumor 
necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), to expand the inflammatory microenvironment of MSCs. 
The severity of colitis and colon cancer was evaluated by measuring colon length, Myeloperoxidase (MPO) activity, 
Hematoxylin-eosin STAINING, Western Blot, Immunohistochemistry and Immunofluorescence. These techniques 
were also performed to analyze the mechanisms of inflammatory cytokines-activated-MSCs in mice colitis and colon 
cancer. Real-time PCR and Enzyme-linked Immunosorbent Assay (ELISA) were used to measure the secretion of pro-
inflammatory factors. Results: We found that the incubation of MSCs with TNF-α and IFN-γ aggravates colitis, where 
high levels of pro-inflammatory factors, such as interleukin (IL)-17, IL-8, IL-12, IL-1β, transforming growth factor 
(TGF)-β, TNF-α and IFN-γ, were secreted. Furthermore, this phenomenon was associated with the activation of the 
nuclear factor-kappa-B (NF-κB)/Signal transducer and activator of transcription three (STAT3) pathway. In addition, 
our study demonstrated that TNF-α and IFN-γ pretreated MSCs synergistically exacerbated mice colon cancer, which 
was closely associated with angiogenesis. Conclusions: Taken together, these results indicate that TNF-α and IFN-γ 
pretreatment effectively inhibited the repair ability of MSCs and accelerated inflammation and tumor progression 
involving NF-κB/STAT3 pathway and angiogenesis-related factors.
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Introduction
Ulcerative colitis (UC) is a chronic inflammatory 
disorder of the colon, characterized by a wide 
range of signs and symptoms such as abnor-
mal pain, mucosal ulceration, and hematoche-
zia. UC and Crohn’s disease (CD) is known as 
the two main forms of inflammatory bowel dis-
ease (IBD), that is defined as an autoimmune 
disease, implicated in an aberrant and persis-
tent inflammation of the bowel [1].
In developed countries, patients with IBD have 
an increased risk of 10-15% developing colo- 
rectal cancer (CRC) [2]. CRC, the third most 
common cancer in western countries and the 
second leading cause of cancer death, is one 
of the most effectively studied topics in recent 
years [3, 4]. Although the percentage of colitis-
associated colon cancer (CAC) was approxi-
mately 2% among all CRC cases, it drew more 
attention due to insights into the connection 
between inflammation and colon cancer [5].  
Although the molecular pathogenesis of IBD 
remains unclear, bacterial translocation across 
a defective intestinal mucosal barrier is regard-
ed as a key driving mechanism of an imbal-
anced intestinal immune response and disease 
progression [6]. Current pharmacotherapeutic 
approaches for IBD treatment is multimodal, 
including antibiotics, corticosteroids, thiopu-
rines, folic acid antagonists and biological ther-
apy using anti-inflammatory cytokines. In addi-
tion, cellular therapy, especially involving mes-
enchymal stem cells (MSCs), is a promising 
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strategy to modulate the immune system for 
IBD treatment [7-10]. Similarly, previous stud-
ies reported the role of MSCs in IBD-mediated 
tumorigenesis that was determined through an 
AOM/DSS colitis-associated carcinoma model. 
Chen et al. demonstrated that BMSCs alleviat-
ed the severity of CAC in mice by suppressing 
the expression of pro-inflammatory cytokines 
(TNF-α, IL-1β and IL-6) and by activating STAT3 
[11]. Nasuno et al. also demonstrated that 
BMSCs partially canceled AOM-induced tumor 
initiation and inhibited the acute apoptotic re- 
sponse to a genotoxic carcinogen (AARGC) in 
colonic epithelial cells [12]. Furthermore, umbil-
ical cord tissue-derived MSCs could prevent 
neoplasm and inhibit chronic inflammation me- 
diated by Smad2 signaling in the CAC model 
[13]. Therefore, it is essential to investigate 
the molecular mechanisms of MSCs positive 
effects on the functionality of colitis and in a 
mouse AOM/DSS colitis-associated carcinoma 
model.
MSCs possess the characteristics of self-
renewal, tissue regeneration, immunosuppres-
sive and potentially immune-modulatory po- 
tencies, and are currently under investigation 
for an IBD alternative therapy via inhibiting the 
expression of inflammatory factors [7]. Pourg- 
holaminejad et al. showed that MSCs posse- 
ssed the ability to incorporate into inflamma-
tion sites and to maintain the immunomodula-
tory function in cytokine-based treatment [14]. 
Among the pro-inflammatory cytokines, TNF-α, 
IFN-γ, IL-1, IL-4 and IL-6, TNF-α and IFN-γ play 
crucial roles in the MSCs immune regulation. 
Meanwhile, our group has found noticeable in- 
creases in TNF-α and IFN-γ expression in colitis 
mice (Supplementary Figure 1B, 1C). Nowadays, 
many studies reported the combined influence 
of pro-inflammatory cytokines TNF-α and IFN-γ 
on MSCs. According to the latest report, the 
stimulation of MSCs with pro-inflammatory fac-
tors, promoted osteoblasts proliferation, migra-
tion, differentiation and mineralization through 
paracrine-related mechanisms. Liu et al. first 
demonstrated that MSCs pre-stimulation by 
TNF-α and IFN-γ could provoke C26 colon can-
cer growth in mice [15-22]. However, little is 
known about the effect of combining MSCs 
transplantation with TNF-α and IFN-γ on colitis 
and CAC in vivo. Therefore, the main aim of the 
present study was to explore potential effects 
and mechanisms of TNF-α and IFN-γ pretreated 
MSCs on DSS-induced colitis and AOM/DSS-
induced colitis, and their association with colon 
cancer, to provide evidence for future studies. 
Material and methods
Experimental animals
Male BALB/c and C57/BL6 mice weighing ap- 
proximately 18-20 g and aged 5 to 6 weeks 
old were used in the experiments. All mice 
were maintained under SPF conditions and 
raised under standard laboratory conditions 
with a 12 h day/night cycle in Xiamen Univer- 
sity Laboratory Animal Center. All animal proce-
dures were approved by the Animal Care and 
Use Committee of Xiamen University, China 
(license No: SYXK [Min] 2008-0003, issued on 
May 6, 2008).
Reagents and cell culture
Dextran Sulfate Sodium (DSS, 36-50 kDa MW, 
from MP Biomedical, Solon, OH), Antibodies 
against NF-κB (p65) and IκBa were purchased 
from Santa Cruz. Anti-pSTAT3 (Y705) was pur-
chased from Cell Signaling Technology. Ki67 
and PCNA were from Abcam. MSCs cell line was 
obtained from the Institute of Biochemistry and 
Cell Biology, Chinese Academy of Sciences 
(Shanghai, China), and was cultured in α-MEM 
medium containing 10% FBS, 1% L-glutamine, 
100 units/ml penicillin, and 100 mg/L strepto-
mycin at 37°C in a 5% CO2/95% air.
DSS-induced colitis and AOM/DSS-induced 
colitis-associated colon cancer model
Male BALB/c mice were divided into experimen-
tal and control groups. Experimental groups 
with DSS-induced colitis were treated or not 
with MSCs (or by TNF-α and IFN-γ treated with 
for 6 h, 24 h, 48 h). Colitis was induced by orally 
administered of 3% (w/v) DSS solution daily. 
The normal control group was treated with 
double distilled water alone. MSCs group re- 
ceived intravenous injection of mesenchymal 
stem cell for 3 days after DSS treatment. The 
body weight, stool consistency, and blood in 
the feces were examined daily to assess the 
extent of DSS-induced colitis in mice.
Figure 4A outlines the inducement of this 
model; briefly, AOM (10 mg/kg body weight, 
i.p) was administered to mice by a single intra-
peritoneal (i.p.) injection. Five days later, mice 
exposed to 3% DSS (wt/vol) in drinking water 
for 5 consecutive days followed by 12 days of 
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regular drinking water. Then, this cycle was 
repeated twice by 2% DSS due to the mass 
mortality of 3% DSS. At the same time, as 
shown in Figure 4A, MSCs were injected by tail 
vein for 1×106 cells each mouse. Body weight 
was assessed according to Figure 4B through-
out the course of the experiment. 
Analysis of colon injury
Paraffin-embedded tissue sections of Swiss-
rolled whole colon (rolled from the distal end 
to the proximal end) were stained with hema-
toxylin and eosin for light microscopic examina-
tion to assess colon injury and inflammation. 
Samples from the entire colon were examined 
by a pathologist blinded to treatment condi- 
tions.
Blood samples and mice tissues
After MSCs injection, mice were scarified and 
1-mL orbital blood sample was collected. The 
abdomen was opened along the median line. 
Then the colon was rapidly excised, gently 
washed with ice-cold PBS, placed on ice, and 
opened longitudinally. The colon was incised, 
and the fecal contents were washed out gently 
within PBS. The blood samples were injected 
into dry test tubes and separated by centrifuga-
tion, and the serum was stored at -80°C until 
use. And then the colon was embedded into the 
dry tubes and stored at -80°C until use.
Immunofluorescence staining
The colon tissues were fixed in 10% formalde-
hyde and embedded in paraffin. Tissue sec-
tions were permeabilized and blocked in PBS 
containing 0.3% Triton X-100 (Sigma-Aldrich, 
Milwaukee, WI) and 10% goat serum, followed 
by staining with primary antibodies for p65 
(1:300) overnight at 4°C and secondary anti-
body (1:200). p65 proteins were then detect- 
ed and immunolocalized using Mounting Medi- 
um containing DAPI. All the sections observed 
using fluorescence microscopy. Cultured cells 
immunofluorescence staining was performed 
as previously described [14]. Image-pro plus 
software was used to quantify the staining den-
sity. Based on the principles of equidistance, 
we randomly chose five views of distal end of 
the colonoscope in each section using 20× 
image, quantified the averaged IOD of each 
section. Every group has prepared 10 sections. 
The averaged IOD of each group was compared 
by Student’s t-test.
Immunohistochemical staining
The colon tissues were fixed in 10% formalin 
and embedded in paraffin. Tissue sections 
were cut, dewaxed, and incubated in 0.01 M 
natrium citricum for antigen retrieval. The slides 
were rinsed in phosphate-buffered saline and 
incubated overnight at 4°C with diluted anti-
Ki67, CD34, p-Stat3 or anti-PCNA antibodies. 
Following steps were performed using the im- 
munostaining kit (Maixin BIO, Fuzhou, China) 
according to the manufacturer’s instructions. 
Enzyme-linked immunosorbent assay
Weighing the same weight of colon organiza-
tion, fixed with pre-cooling PBS (1:9), homoge-
neous mixed, and centrifugated (10000 rpm/
min, 10 min). The supernatant was reserved. 
The MSCs were treated with TNF-α and IFN-γ 
for 24 hours in the DSS treated mice. After 
treatment, the supernatants of tissues were 
collected and centrifugalized (1000 rpm/min, 
5 min). The production of IL-1β, IL-17, TNF-α, 
IFN-γ and IL-10 in colon tissues supernatants 
and blood serum were determined in duplicate 
using ELISA kit (R&D System Europe Ltd., UK) 
as described by the manufacturer.
Western blotting analysis
Samples were collected by lysing cells in RIPA 
lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 
1 mM ethylenediaminetetraacetic acid (EDTA), 
0.1% SDS, 1% TritonX-100, 1% sodium deoxy-
cholate, and 1 mM phenylmethylsulfonyl fluo-
ride (PMSF). Each sample was size-fractiona- 
ted using SDS-polyacrylamide gel electroph- 
oresis (PAGE) and transferred onto polyvinyli-
dene difluoride (PVDF) transfer membranes 
(DuPont, Boston, MA, U.S.A.). Blots were incu-
bated for 1 h at room temperature in 5% skim 
milk for blocking, and proteins were detected 
with primary antibodies overnight at 4°C, and 
then blotted with peroxidase-conjugated conju-
gated secondary antibodies for 1 hour at room 
temperature. The immunoblots were visualized 
using ECL (GE Healthcare, Bucks, UK). 
Real-time PCR
Cells were collected to extract the total cellular 
mRNA using TRIzol reagent (Invitrogen). cDNA 
was synthesized using Moloney murine leuke-
mia virus reverse transcriptase (Promega) and 
2 μg of total RNA and oligo (dT) 18 primers. 
Two-microliter aliquots of cDNA were used for 
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PCR amplification. Real-time PCR was perform- 
ed in triplicate using the SYBR Prime Script 
RT-PCR Kit (Takara, Dalian, China). Thermocy- 
cler conditions included an initial hold at 50°C 
for 2 min and then 95°C for 10 min; this was 
followed by a two-step PCR program of 95°C 
for 15 s and 60°C for 60 s repeated for 45 
cycles on a LightCycler®96 system (Roche, Sh- 
anghai, China), on which data were collected 
and quantitatively analyzed.
In vivo imaging of homing ability to tumors 
We use Cell Tracer CM-Dill (Invitrogen Life Tech- 
nologies, CA, USA) to trace MSCs in vivo. CM- 
Dil working solution was prepared as the ma- 
nufacturer’s instructions. Briefly, 1 mg CM-Dil/
mL stock solution in culture-grade DMSO, 8 μM 
solutions were made in 500 μL PBS, vortexed, 
and then combined with 2×106 hUC-MSCs in 
500 μL PBS, to give 106 cells/mL in 4 μM CM-Dil 
labeling solution. CM-Dil cell suspensions were 
incubated for 30 min at 37°C and then for 15 
min at 4°C. After labeling, cells were washed 
three times with PBS and resuspended in fresh 
medium. 24 hours after staining, cells were in- 
jected into the mice by tail vein, and then opti-
cal bioluminescence imaging was conducted to 
periodically trace the cells using a maestro in 
vivo imaging system (CRI, MA, USA). 
Statistical analysis
All data are presented as the means ± S.D. for 
at least three separate determinations for each 
group. The differences between the groups we- 
re examined for statistical significance using 
the Student’s t-test with SPSS software. Differ- 
ences were considered significant when the 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Results
MSCs pretreatment with TNF-α and IFN-γ ag-
gravates mice colitis
Accumulating evidence showed that migration 
and homing of MSCs to the injured tissue con-
tribute to the development of inflammation and 
wound healing, through autocrine or paracrine 
cytokines interacting with damaged tissues. To 
investigate this MSCs-mediated function, the 
DSS-induced experimental model of ulcerative 
colitis was constructed. It is characterized by a 
severe inflammation, such as massive mucosal 
damage, loss of goblet cells, crypt reduction 
and accumulation of infiltrating neutrophils in 
the lamina propria (Supplementary Figure 1A). 
Both TNF-α and IFN-γ were expressed abun-
dantly during the active phase of UC when the 
DSS-induced colitis model was successfully 
established (Supplementary Figure 1B and 1C). 
The expression of the embryonic stem cell 
markers SOX2 and Nanog [23] indicated that 
MSCs preferentially migrated toward inflam- 
mation sites rather than normal sites (Supple- 
mentary Figure 2A). We found that MSCs pre-
treated with TNF-α and IFN-γ for 72 h could 
accumulate in the caecum (Supplementary 
Figure 2B). In a previous study, it was reported 
that the ability of MSCs to preferentially migr- 
ate toward the sites of tissue damage and in- 
flammation, was related to surface chemokine 
receptors or inflammation cytokines, such as 
CXC chemokine receptors 1 and 2 (CXCR1 and 
CXCR2), CXCR4 and, monocyte chemoattrac-
tant protein 1 (MCP-1) [24-26]. We detected 
CXCR4 and MCP-1 mRNA expression levels in 
each group, as they are involved in MSCs mo- 
bilization (Supplementary Figure 2C and 2D). 
Consequently, MSCs play an important role by 
homing to the injured sites. 
To compare with the DSS and MSCs treated 
group, our study confirmed clear decreases in 
body weight loss and colon length in the TNF-α 
and IFN-γ treated group (Figure 1A and 1B). 
Myeloperoxidase (MPO) activity is a represen- 
tative of neutrophil infiltration and is consid-
ered to be an important indicator of inflam- 
mation degree. Therefore, we investigated the 
MPO activity (Figure 1C) and found that its le- 
vel was clearly increased following the addition 
of TNF-α and IFN-γ to MSCs. Similarly, cytokines 
treated group tended to exacerbate the inflam-
mation as determined by HE staining, that 
showed a loss of structure of the mucosa and 
lamina propria, a loss of goblet cells, advanced 
damage to the crypt and increased neutrophils 
infiltration, when compared to the other groups 
(Figure 1D).
Hence, the MSCs group had a remarkable 
remission that was reflected by the change in 
body weight, colon length, reduction of MPO 
level and a noticeable tissue repair in mice with 
colitis. Yet when the MSCs were injected into 
mice tail vein, following treatment with TNF-α 
and IFN-γ, the repair function was profoundly 
inhibited. 
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MSCs treated with TNF-α and IFN-γ aggravate 
mice colitis via the NF-κB/STAT3 signaling 
pathway
MSCs, which are modulated by cytokines pres-
ent in the inflammation microenvironment, play 
an important role in the repair of colitis in mice. 
However, the underlying mechanisms involved 
are not well known. According to a previous 
study, IFN-γ and TNF-α synergistically impair 
MSCs via the NF-κB-mediated activation of 
Mothers against decapentaplegic homolog 7 
(SMAD7) in ovariectomized (OVX) mice [19]. In 
this study, we investigated the combined effect 
of IFN-γ and TNF-α on MSCs by in vitro pretreat-
ments of MSCs with IFN-γ (50 ng/mL) and 
TNF-α (10 ng/mL) for 6 hours, 24 hours and 72 
hours These treatments resulted in the activa-
tion of the NF-κB pathway leading to P65 up-
regulation and IκBα downregulation (Figure 2A, 
Supplementary Figure 3). Meanwhile, we 
observed by immunofluorescence Staining, an 
accumulation of P65 in the nucleus, 24 h fol-
lowing treatment (Figure 2B). Simultaneously, 
the expression of p65 and p-STAT3 were both 
higher in the group treated with TNF-α and 
IFN-γ for 24 h in vivo (Figure 2C and 2D). The 
results above infer that the administration of 
TNF-α and IFN-γ activated the NF-κB/STAT3 
pathway of MSCs in mice colitis.
Effect of MSCs pretreatment with TNF-α and 
IFN-γ on the immune microenvironment of 
mice colitis
Previous studies demonstrated that IBDs have 
a close connection with a dysregulated dialog- 
Figure 1. MSCs pretreated 
by TNF-α and IFN-γ aggra-
vated the mice colitis. A and 
B. In comparison to the DSS 
and MSCs treated group, the 
group treatment with TNF-α 
and IFN-γ show a more obvi-
ous decrease in the loss of 
body weight and colon length. 
C. Intervention of TNF-α and 
IFN-γ to the MSCs induced 
the elevation of MPO activ-
ity in mice colon. D. The HE 
staining of each group dem-
onstrated more serious de-
struction epithelial architec-
ture and inflammatory cellular 
infiltration in TNF-α and IFN-γ 
treatment group. (Data were 
presented with mean ± SD 
of three independent experi-
ments, *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001).
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ue between intestinal microbiota and compo-
nents of both the innate and adaptive immune 
systems. Cytokines, including TNF-α, IFN-γ, IL- 
1β, IL-6 and IL-10, play essential roles in medi-
Figure 2. MSCs treated with TNF-α and IFN-γ affects the mice colitis via NF-κB/stat3 signaling pathway. A. Pre-
treated the MSCs with TNF-α (10 ng/mL) and IFN-γ (50 ng/mL) for 6 h, 24 h, 72 h, then detecting the expression of 
p65 and IκBα. B. Pre-treated the MSCs with TNF-α (10 ng/mL) and IFN-γ (50 ng/mL) for 6 h, 24 h, 72 h, then the ex-
pression and location of p65 were detected by immunofluorescence. C. The immunofluorescence results illustrated 
the enhanced p65 expression when MSCs were pretreated with TNF-α and IFN-γ from colon tissues. D. The higher 
expression of p-stat3 was detected in the group treated with TNF-α and IFN-γ in colon tissues by immunohistochem-
istry. (Images were representative of three independent experiments). 
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ating the crosstalk between activated immune 
and non-immune cells, such as epithelial and 
mesenchymal cells [27]. For example, TNF-α, 
which is one of the earliest and most important 
mediators, released in the process of inflam-
mation, activates neutrophils and lymphocytes 
that are involved in the increase of vascular 
permeability and the regulation of metabolism 
activity of other tissues. This activation also 
promotes other cytokines production and re- 
lease, and plays a crucial role in the initiation 
and amplification of inflammatory reactions in- 
volved in tissue damage and repair [28]. 
Meanwhile, our research indicated that the 
autocrine and paracrine activity of MSCs was 
associated with wound healing and inflamma-
tory response. We analyzed protein expression 
and mRNA levels of inflammatory factors in 
colon tissue, serum, and plasma by Elisa and 
RT-PCR. The level of inflammatory cytokines in 
the serum of each group has been determined 
when MSCs were stimulated with TNF-α and 
IFN-γ, especially correlative increases in expres-
sion of pro-inflammatory factors, such as IL-17, 
TNF-α, IL-1β, IFN-γ and the anti-inflammatory 
IL-10 (Figure 3A-E). Similar expression pattern 
could also be seen in colon tissue of each 
group (Figure 3F-J) for TNF-α and IL-1β mRNA 
levels in plasma (Figure 3K and 3L). Therefore, 
these results showed that MSCs modulate 
wound healing through regulating the release 
of inflammatory factors, and the expression 
and secretion of inflammatory cytokines, that 
are associated with the NF-κB pathway in 
MSCs.
TNF-α and IFN-γ pretreated MSCs exacerbate 
mice colon cancer
As shown in Figure 4A, an azoxymethane 
(AOM)/dextransulfate sodium (DSS)-induced 
mice models were established and adminis-
tered with or without MSCs, MSCs pretreated 
with TNF-α and IFN-γ or without, and for 6 h, 
24 h and 48 h, to examine macroscopically and 
histologically, the severity of CAC. Significant 
body weight loss was observed in AOM/DSS 
induced mice when compared with the control 
group (Figure 4B), and most of the injected 
groups. Moreover, the body weight loss was 
lower in the MSCs group and the 48 h TNF-α 
and IFN-γ pretreated group, when compared to 
body weight loss in the AOM/DSS model group 
(*P<0.05).
Macroscopically, MSCs markedly decreased 
the incidence, number, and size of the tumor. 
However, cytokines treated groups revealed 
positive effects on tumor formation (Figure 4C). 
We next evaluated the histopathological char-
acteristics of tumor tissue samples from each 
group by Hematoxylin and eosin (H&E) staining. 
In comparison with the AOM/DSS model group, 
cytokines treated groups exhibited more irregu-
lar tubular structures, multiple lumens and a 
reduced stroma (“back to back” aspect) (Figure 
4C). Consequently, treatment with MSCs allevi-
ated colon cancer tumorigenesis, consistent 
with previous studies using animal models, 
however, the combined treatment with TNF-α 
and IFN-γ has the opposite effect on MSCs.
The pretreated MSCs enhance angiogenesis 
and cell proliferation in mice colon cancer
To determine the effects of the pretreated 
MSCs on tumorigenesis and cell proliferation, 
we investigated the expression of several mark-
ers which are closely related with these pro-
cesses. MSCs had a remarkable inhibition of 
MMP9 and VEGF expression (Figure 5A and 
5B). However, cytokines treated groups sharply 
impair their effects. Besides, high expression 
of CD34 in these groups reinforced and con-
firmed the crucial role of pre-treatments with 
inflammatory factors (Figure 5C). Further evi-
dence based on the enhanced expression of 
PCNA and Ki67 after cytokines stimulation, 
confirmed our conclusions that the combina-
tion of TNF-α and IFN-γ increases angiogenesis 
and cell proliferation in CAC mice (Figure 5D).
Influence of MSCs pretreatment with TNF-α 
and IFN-γ on the immune regulation of mice 
colon cancer
It has been shown that MSCs have the ability to 
migrate into tumors and injury sites by sensing 
signaling molecules, which are released from 
distant damaged tissues, due to the increase 
of inflammatory mediators [29]. To investigate 
this, mRNA expression changes of several re- 
lated cytokines in mice were determined, and 
we found that weaker expression of all detect-
ed cytokines, especially TGF-β, COX-2, IL-6 and 
IL-8, in the MSCs group when compared to the 
AOM/DSS-induced CAC group (Figure 6A-F). 
Additionally, cytokines release in the pre-treat-
ed MSCs was time independent. For instance, 
the highest expression of TNF-α occurred in the 
48 h group, while the strongest expression of 
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COX-2 was observed in the 24 h group, and the 
maximum expression of IL-6 and IL-8 were no- 
ticed in the 6 h group. We attribute these differ-
ences to the diversity in cytokines synthesis 
and secretion. Taken together, our results indi-
cate that MSCs regulate the immune system by 
Figure 3. TNF-α and IFN-γ synergistically stimulate MSCs impacting the cytokines expression in each group. A-E. The 
expressions of IL-17, TNF-α, IL-1β, IFN-γ and IL-10 were detected in each group from mice serum. F-J. The expres-
sions of IL-17, TNF-α, IL-1β, IFN-γ and IL-10 were also detected in each group from mice colon tissue. K, L. The mRNA 
levels of TNF-α and IL-1β were showed in mice plasma (Data were presented with mean ± SD of three independent 
experiments, *P<0.05, **P<0.01).
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Figure 4. TNF-α and IFN-γ synergistically induce the MSCs exacerbating the mice colon cancer. A. Schematic dia-
gram of experimental methods for AOM/DSS-induced colitis-associated colon cancer model with or without MSCs/
MSCs treated with TNF-α and IFN-γ for 6 h, 24 h and 48 h. B. Significant body weight loss was observed in AOM/
DSS model group and TNF-α and IFN-γ/48 h group. C. Gross view of mice colon tissue and HE staining revealed 
that cytokines treatment groups up-regulated the incidence, number and size of the tumor and presented more 
irregular tubular structures, multiple lumens and reduced stroma. (Data were presented with mean ± SD of three 
independent experiments, *P<0.05).
suppressing the release of inflammatory fac-
tors in mice, to promote wound healing, where-
as, the use of TNF-α and IFN-γ synergistically 
weakens their repair function.
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Discussion
The multilineage differentia-
tion capacity of MSCs, and 
their immunomodulatory ac- 
tivity, implied that these 
somatic progenitor cells are 
highly versatile for a wide 
range of therapeutic appli- 
cations [30]. In the etiology 
and progression of human 
IBD, including CD and UC 
are multifactorial, uncontroll- 
ed immune responses to in- 
testinal microbes are one 
of the critical players [31]. 
Both CD and UC are progres-
sively fatal without curative 
treatment. In recent years, 
an increasing number of re- 
ports consistently showed 
that MSCs could be applied 
for the treatment of infla- 
mmation-mediated diseases. 
For example, a study based 
on a new model for chronic 
IBD, which was established 
by an alternative administra-
tion periods of DSS, showed 
a great potential in improving 
the stool condition, weight 
gain, the normal histopatho-
logic picture, and in decreas-
ing gene expression of in- 
flammatory markers such as 
IL-23, TNF-α and IFN-γ associ-
ated with the therapeutic use 
of MSCs in treating IBD [32]. 
Furthermore, multi-mechani- 
sms involving the efficacy of 
MSCs treatment have been 
proved, such as the induction 
of IL-10 secreting regulatory T 
cells [33], the down-regula-
tion of IL-23/IL-17 regulated 
inflammatory reactions and 
the modulation of Treg/Th17 
Figure 5. The pretreated MSCs enhance the angiogenesis and cell prolifera-
tion in mice colon cancer. A and B. The higher expression of MMP9 and VEGF 
was observed in cytokines treatment groups from mice blood. C. The black 
arrows pointed out more presence of CD34 in the pretreated MSCs groups 
than the other groups by immunohistochemistry. D. Immunohistochemistry 
of PCNA and Ki67 in murine in-
testine. Strong positive staining 
in the intestine of MSCs pre-treat-
ment with inflammatory factors 
mice. (Data were presented with 
mean ± SD of three independent 
experiments, *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001).
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cells [34]. It was also found that MSCs had 
tumor suppressive properties in CAC models 
and from different species with bone marrow 
or cord blood origin [35]. 
In our study, similar results were obtained on 
the positive effects of MSCs in the DSS and 
AOM/DSS models in mice. These effects sig-
nificantly delayed body weight changes, impro- 
ved colon tissue damage, as assessed by visu-
al observation and microscopy, and reduced 
the expression of pro-inflammatory factors (IL-
1β, TNF-α, IL-6, IL-12, and COX-2) when com-
pared to the PBS groups (Figure 6). Meanwhile, 
the lower expression of KI67, PCNA, CD34, 
VEGF and MMP9 in the MSC group may infer 
that MSCs have negative effects on the devel-
opment of colon carcinoma by decreasing tu- 
mor cell proliferation and angiogenesis (Figure 
5). Furthermore, we also discovered that the 
potential mechanisms associated with MSCs 
effects may rely on exerting forward influences 
on colitis and CAC through the inhibition of the 
NF-κB/STAT3 pathway (Figure 2). 
In addition, previous reports on TNF-α and 
IFN-γ synergistically inducing MSC deficiency 
and tumorigenesis in OVX-induced osteoporo- 
tic mice, are consistent with our findings on the 
exposure of MSCs to TNF-α and IFN-γ via the 
activation of the NF-κB signaling in colitis mice 
(Figure 2) [19]. Moreover, we demonstrated 
that pretreated MSCs possess the ability to 
promote the tumor progression in CAC mice 
(Figure 5). It was previously described that pre-
treated MSCs with TNF-α and IFN-γ, promote 
Figure 6. Influence of MSCs treatment with TNF-α and IFN-γ on the immune regulation of mice colon cancer. A-F. The 
mRNA level of TNF-α, TGF-β, COX-2, IL-6, IL-8 and IL-12 were weaker in MSCs group than in AOM/DSS-induced CAC 
model group and the release of cytokines in the pre-treated MSCs was independent of the treatment time from mice 
blood (Data were presented with mean ± SD of three independent experiments, *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001). 
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tumor angiogenesis through upregulating the 
expression of VEGF, which is associated to the 
hypoxia-inducible factor 1α (HIF-α)-dependent 
signaling [17]. Similarly, we confirmed that the 
stimulation of MSCs with two cytokines not 
only upregulated the level of VEGF expression, 
but also MMP9 and CD34 expression levels. 
However, the mechanism behind MSCs angio-
genic ability is not completely understood. In a 
most recent study, it has been well established 
that TNF-α preactivated-hMSCs exert a much 
stronger tumor-promoting effect via the CCL5/
β-catenin/Slug pathway in CRC progression 
[36]. Accordingly, we can suppose that MSCs, 
pre-activated with TNF-α and IFN-γ, promote 
CAC proliferation that involves the CCL5/β- 
catenin/Slug pathway.
The Lixin Wei group demonstrated that the 
combined use of TNF-α and IFN-γ caused a 
significant up-regulation of TGF-β expression 
in MSCs, which induced autophagy and chemo-
resistance in hepatocellular carcinoma cells 
(HCC) [20]. Afterwards, a research showed that 
TNF-α and IFN-γ synergistically promote the 
ability of human placenta-derived MSCs to 
enhance the expression of programmed death 
ligand-2 and CD4+IL-10+ and CD8+IL-10+ Treg 
subsets from T cells [21]. Recently more stud-
ies were performed in vitro, such as the one 
from Haibin Zhou group which showed that pre-
stimulated MSCs produce more IL-6, HGF, VEGF 
and TGF-β but not IL-2, IL-4 and IL-10 [15]. Ping, 
et al. confirmed that stimulation with TNF-α and 
IFN-γ polarized MSCs to a Th1 phenotype, 
resulting in the release of IL4, IL-10, CD274/
PD-L1 and IDO [22]. Besides, it was also report-
ed that TNF-α and IFN-γ synergistically induced 
the expression of IGF-1, TGF-β, Qa2 and pluri-
potency genes by significantly promoting the 
proliferation of murine adipose tissue-derived 
MSCs [37]. Interestingly, these studies corre-
late with ours, in that TNF-α together with IFN-γ 
increased the immuno-modulatory effects of 
MSCs on colitis and CAC mice by expressing 
more cytokines including TNF-α, IFN-γ, IL-10, 
IL-1β, IL-17, TGF-β, COX-2, IL-8 and IL-12. There- 
fore, our study confirmed that the pre-stimulat-
ed MSCs with TNF-α and IFN-γ can exacerbate 
mice colitis and CAC by decreasing body wei- 
ght, worsening colon tissues damage, facilitat-
ing the expression of pro-inflammatory factors, 
and in contrast with what was observed in the 
PBS and MSCs groups. Consequently, we con-
cluded that the pre-treated MSCs negatively 
affected colitis-related disease in mice via acti-
vating NF-κB/STAT3 pathway. In the CAC study, 
we also found, that the two factors TNF-α and 
IFN-γ, possessed the ability to promote prolif-
eration and angiogenesis stimulated by MSCs 
in CAC mice.
It should be noted that this study only exam-
ined, in vivo, the effects of pretreated MSCs, 
with two pro-inflammatory cytokines, and did 
not focus on exploring, in vitro, possible mecha-
nisms affecting the immunophenotype and im- 
muno-modulatory actions of combining TNF-α 
and IFN-γ on MSCs. Overall, our study investi-
gated, for the first time, the effects of TNF-α 
and IFN-γ pre-treated MSCs in colitis and CAC 
model, and demonstrated that the two pro-in- 
flammatory cytokines efficiently reversed the 
repairing function of MSCs in colitis. It also sug-
gests that these effects are potentially associ-
ated with the sensitization of the NF-κB/STAT3 
pathway. Undoubtedly, these findings would lay 
a solid foundation for further investigations.
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Supplementary Figure 1. (A) Representative haematoxylin-eosin staining of colons of mice receiving water (control) 
and dextran sulfate sodium (DSS). Compared with that of normal controls, the colons of DSS-treated mice showed 
destruction of epithelial architecture and inflammatory cellular infiltration. (n=3 independent experiments). (B and 
C) The mice with DSS treatment secret more IFN-γ (B) and TNF-α (C) than control group in serum (n=4 independent 
experiments).
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Supplementary Figure 2. A. MSCs migrated and homing at the injury colon. The DSS-induced group exhibits higher 
expression of MSCs markers SOX-2 and Nanog in colitis mice colon than the normal mice ones. B. Compared with 
MSCs treatment in DSS-induced group, significantly higher homing and migration ability was detected when MSCs 
were pretreated with IFN-γ and TNF-α by in vivo imaging. C and D. In comparison to other groups, the MSCs treat-
ment with IFN-γ and TNF-α showed increased mRNA level of MCP-1 and CXCR4 in plasma (n=3 independent experi-
ments). 
Supplementary Figure 3. Original images for all relevant western blots in Figure 2A.
